Table 2.
Five-year disease-specific survival in patients receiving surgery without preoperative chemotherapy by subgroup
| FMUUH (n=4,171) | MSKCC (n=733) | p | |||
|---|---|---|---|---|---|
| 5-year DSS | 95% CI | 5-year DSS | 95% CI | ||
| All patients | 61% | 0.590-0.630 | 80% | 0.761-0.839 | <0.001 |
| TNM stage | |||||
| Stage IA | 95% | 0.930-0.970 | 96% | 0.940-0.980 | 0.920 |
| Stage IB | 92% | 0.881-0.959 | 87% | 0.792-0.948 | 0.139 |
| Stage IIA | 85% | 0.811-0.889 | 85% | 0.752-0.948 | 0.813 |
| Stage IIB | 78% | 0.741-0.819 | 67% | 0.552-0.788 | 0.288 |
| Stage IIIA | 63% | 0.571-0.689 | 61% | 0.473-0.747 | 0.777 |
| Stage IIIB | 50% | 0.461-0.539 | 57% | 0.433-0.707 | 0.227 |
| Stage IIIC | 30% | 0.280-0.320 | 35% | 0.174-0.526 | 0.229 |
| T category | |||||
| T1 | 94% | 0.920-0.960 | 93% | 0.891-0.969 | 0.508 |
| T2 | 84% | 0.801-0.879 | 82% | 0.722-0.918 | 0.905 |
| T3 | 62% | 0.581-0.659 | 75% | 0.672-0.828 | 0.008 |
| T4 | 43% | 0.410-0.450 | 49% | 0.392-0.588 | 0.034 |
| N category | |||||
| N0 | 90% | 0.880-0.920 | 91% | 0.871-0.949 | 0.512 |
| N1 | 76% | 0.721-0.799 | 76% | 0.662-0.858 | 0.731 |
| N2 | 59% | 0.551-0.629 | 63% | 0.493-0.767 | 0.445 |
| N3 | 32% | 0.300-0.340 | 48% | 0.362-0.598 | 0.001 |
| Histology | |||||
| Differentiated | 77% | 0.750-0.790 | 89% | 0.851-0.929 | <0.001 |
| Undifferentiated | 55% | 0.530-0.570 | 75% | 0.711-0.789 | <0.001 |
| Tumor location | |||||
| Proximal | 57% | 0.531-0.609 | 78% | 0.721-0.839 | <0.001 |
| Middle | 59% | 0.551-0.629 | 77% | 0.692-0.848 | <0.001 |
| Lower | 68% | 0.660-0.700 | 83% | 0.771-0.889 | <0.001 |
| Mixed | 47% | 0.431-0.509 | 86% | 0.703-1.017 | 0.005 |
| Type of gastrectomy | |||||
| Total | 53% | 0.510-0.550 | 76% | 0.682-0.838 | <0.001 |
| Distal | 71% | 0.690-0.730 | 83% | 0.791-0.869 | <0.001 |
| Proximal | 69% | 0.572-0.808 | 78% | 0.702-0.858 | 0.198 |